Entrada Therapeutics, Inc.
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access. Its pipeline is focused on neuromuscular and inherited retinal diseases, with lead programs in Duchenne muscular dystrophy and a partnered myotonic dystrophy program with Vertex.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead exon-skipping and genetic medicine candidates for Duchenne muscular dystrophy.
VX-670 collaboration with Vertex for myotonic dystrophy type 1.
Endosomal Escape Vehicle platform used to deliver therapeutics into cells.
Earlier-stage programs in neuromuscular and inherited retinal diseases.
Customers
Entrada does not yet sell approved products; its current economic counterparties are collaboration partners, regulators, clinical investigators, and trial sites rather than end-market patients. If approved, its therapies would be prescribed by physicians and reimbursed by third-party payors for rare disease patients, especially in neuromuscular and inherited retinal disease populations.
Vertex funds and co-develops VX-670, providing non-product revenue and development support.
Patients with DMD and DM1 who enroll in studies and generate clinical data needed for approval.
Neuromuscular specialists and treatment centers that would diagnose, prescribe, and monitor therapy.
Insurers and public payors that would determine access and reimbursement for any approved medicines.
Strategy
Entrada's strategy is to validate its EEV platform through clinical readouts in DMD and through the Vertex-partnered VX-670 program, then expand into additional indications. Near term, it is focused on advancing multiple clinical trials, securing regulatory filings, and using early data from one program to inform the rest of the pipeline.
Human data is the main value driver for a clinical-stage biotech and de-risks the platform.
Success in one candidate can support the broader pipeline and improve partnering leverage.
Collaboration revenue and external validation reduce funding pressure and broaden development reach.
Geography
Entrada is headquartered in the United States, but its clinical development footprint spans the U.S., the U.K., and the European Union. The company specifically highlighted DMD programs in the U.K., EU, and U.S., and it expects an EU filing for ENTR-601-50, making Europe an important regulatory and trial geography.
Risks
Entrada is exposed to the binary risk profile of clinical-stage drug development: programs can fail on safety, efficacy, manufacturing, or regulatory grounds. It also depends on continued financing and on the success of a small number of lead assets, so delays in clinical milestones or partner execution could materially affect the business.
- Clinical development failureImpact: CriticalLikelihood: High
The company has no approved products and relies on a small number of programs to prove efficacy and safety.
Exposure - Regulatory and approval delaysImpact: HighLikelihood: High
Rare-disease programs require multiple agency interactions and can be slowed by additional data requests.
Exposure - Financing riskImpact: HighLikelihood: High
The company expects operating losses and negative cash flow until product sales, if ever, begin.
Exposure - Manufacturing scale-up and supply riskImpact: HighLikelihood: Medium
EEV-based therapeutics have not been manufactured at commercial scale and may be difficult to scale reliably.
Exposure: Clinical and future commercial supply
- Partner concentrationImpact: MediumLikelihood: Low
A substantial portion of revenue to date has come from the Vertex agreement.
Exposure: Collaboration revenue and development support
Accounting
Judgemental itemsRevenue depends on performance obligations and milestone timing under the Vertex agreement.
Impact: Can shift revenue between periods without changing underlying cash generation
Clinical trial, manufacturing, and preclinical costs require accrual estimates and can be volatile.
Impact: Affects operating loss and comparability across quarters
A large portion of employee compensation is equity-based in a development-stage biotech.
Impact: Impacts operating expenses and non-cash dilution analysis
U.S. tax rules require capitalization and amortization of certain R&D costs.
Impact: Affects tax expense and deferred tax timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Sarepta Therapeutics, Inc.
SRPT · Pharmaceutical Preparations
Sarepta Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy,…
Dyne Therapeutics, Inc.
DYN · Pharmaceutical Preparations
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026